Neurosense Net Income From Continuing Ops from 2010 to 2026
| NRSN Stock | USD 0.95 0.00 0.000001% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -9.2 M | Current Value -9.6 M | Quarterly Volatility 4.3 M |
Check Neurosense Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurosense Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 2.2 K, Depreciation And Amortization of 18.8 K or Interest Expense of 373.3 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 12.14. Neurosense financial statements analysis is a perfect complement when working with Neurosense Therapeutics Valuation or Volatility modules.
Neurosense | Net Income From Continuing Ops | Build AI portfolio with Neurosense Stock |
Evaluating Neurosense Therapeutics's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Neurosense Therapeutics's fundamental strength.
Latest Neurosense Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Neurosense Therapeutics over the last few years. It is Neurosense Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurosense Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Neurosense Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (4,220,968) | |
| Coefficient Of Variation | (102.19) | |
| Mean Deviation | 3,713,248 | |
| Median | (1,222,000) | |
| Standard Deviation | 4,313,256 | |
| Sample Variance | 18.6T | |
| Range | 11.1M | |
| R-Value | (0.81) | |
| Mean Square Error | 6.7T | |
| R-Squared | 0.66 | |
| Significance | 0.000071 | |
| Slope | (694,950) | |
| Total Sum of Squares | 297.7T |
Neurosense Net Income From Continuing Ops History
About Neurosense Therapeutics Financial Statements
Neurosense Therapeutics investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Neurosense Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -9.2 M | -9.6 M |
Pair Trading with Neurosense Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurosense Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurosense Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Neurosense Stock
| 0.58 | LION | Lionsgate Studios Holding | PairCorr |
| 0.54 | JRVR | James River Group | PairCorr |
| 0.44 | KNYJF | KONE Oyj Earnings Call This Week | PairCorr |
| 0.39 | CUB | Lionheart Holdings | PairCorr |
| 0.38 | SUNFF | Sun Life Financial | PairCorr |
The ability to find closely correlated positions to Neurosense Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurosense Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurosense Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurosense Therapeutics to buy it.
The correlation of Neurosense Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurosense Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurosense Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurosense Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Neurosense Therapeutics Correlation against competitors. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Biotechnology sector continue expanding? Could Neurosense diversify its offerings? Factors like these will boost the valuation of Neurosense Therapeutics. Anticipated expansion of Neurosense directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neurosense Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Neurosense Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Neurosense Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Neurosense Therapeutics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Neurosense Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neurosense Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Neurosense Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.